Izvorni znanstveni članak

FEASIBILITY OF ALPHA-BLOCKERS IN CHRONIC CATEGORY III PROSTATITIS

Silvio Altarac
Vedran Cindro
Nikola Radović
Zoran Rajković
Stanko Belina

Sažetak

Studies were identified on internet by searching on address: http://www.ncbi.nlm.nih.gov/pubmed/ with criteria that studies should be placebo-controlled and randomized in trials of alpha-blockers in chronic category III prostatitis evaluated by symptom-score NIH-CPSI. From 13 clinical studies three were excluded because of not using NIH-CPSI, three were in Chinese language and two were congress abstracts. Analysed were five studies with four or five Jadad scale including 563 patients. Alpha-blockers alfuzosin, terazosin, tamsulosin and doxazosin have been used through 6 weeks and 6 months. Better results were accomplished by less selective alpha-blockers alfuzosin, terazosin and doxazosin through 3–6 months in patients having higher NIH-CPSI score and higher voiding score.

Ključne riječi

Prostatitis – diagnosis, drug therapy; Adrenergic alpha-antagonists – therapeutic use

Hrčak ID:

171759

URI

https://hrcak.srce.hr/171759

Datum izdavanja:

30.6.2011.

Podaci na drugim jezicima: hrvatski

Posjeta: 2.007 *